Temperature check: How is the CSL (ASX:CSL) share price faring today?

How has the CSL (ASX: CSL) share price been faring lately? We take a look at its latest performance, and the broker price targets.

| More on:
A woman looks surprised as she checks an old-fashion thermometer, indicating a change in share price moevement for biotech companies

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has had a disappointing last couple of weeks, dragged down 9% with the broader ASX market slump in early March.

This comes despite the company posting an impressive set of numbers from its half-year results in February.

Below, we take a closer look at CSL's most recent update and how brokers view the global biotech's shares.

How did CSL perform for the first-half?

In its results, CSL reported that COVID-19 had temporarily impacted CSL Behring's performance during the first half of 2021 while boosting its Seqirus business. Despite the difference, both segments saw an increase in earnings before interest and tax (EBIT) of 24% and 112%, respectively.

This led to a surge of net profit after tax (NPAT) of $1,810 million, a jump of 44% over the prior corresponding period.

The company stated that global demand for its therapies remained strong, particularly with significant growth in seasonal influenza vaccines. The latter is due to the COVID-19 pandemic driving high rates of people getting protected from the flu.

What were the challenges?

While the results themselves were positive, CSL revealed that it continued to face some challenges.

The company advised that plasma collections remained an issue as restrictions on passenger movements affected blood donations through its collection centres.

In the United States, CSL has moved to reach out to donors through targeted marketing initiatives. This includes turning to social media influencers to encourage giving blood, as well as increased monetary incentives.

Collection volumes at the end of last year stood at 80% when compared against December 2019.

In addition, CSL had to re-prioritise some R&D projects, such as halting its efforts to develop a COVID-19 vaccine with the University of Queensland.

It found that during its Phase 1 trial, patients who were undertaking the vaccine candidate were registering as false positives on HIV tests. In light of this, the company decided not to proceed with further phase 2/3 trials.

Broker update

After reporting its first-half results, several brokers rated the company with varying price points.

The Swiss investment firm UBS cut its price target for CSL by 2.7% to $330.00. Morgan Stanley followed suit to also reduce their rating by 2.5% to $276.00, then upgraded in March to an add rating with a $301.10 price target.

According to a note out of Citi, its analysts have upgraded the biotech giant's shares to a buy rating with a $310.00 price target

The most recent broker note came from Macquarie last week, which has initiated a price of $288.00 for the biotech.

At the time of writing, the CSL share price is sitting at $261.81, up 2.33% for today. 

CSL share price review

Over the past 12 months, the CSL share price has lost around 6%, mostly from its year-to-date performance.

The company's shares moved sideways for much of the period before plummeting on its latest results release. It's worth noting that its shares today are priced the same as when they were back in November 2019.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Aaron Teboneras owns shares of CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »